- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04132206
Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients (ScleroBiotique)
ScleroBiotique: Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients
Study Overview
Detailed Description
This is an explorative, prospective, monocentric open-label study qualified as interventional researches at minimal risks and constraints (called in French RIPH, category 2).
This is a study of the gut microbiota and its characteristics in ScS patients, compared to control subjects (without ScS or other chronic diseases), matched on age and sex.
Participants provided two stool samples: one collected the day of inclusion and a second, six months later.
In parallel with the microbiota analysis, a clinical (digestive and extra digestive signs, severity) and biological characterization of the ScS will be carried out by the team of internists. This medical evaluation will be completed by an interview with a dietician to inform about the participant's eating habits, and any changes in the 7 days preceding the stool collection.
Microbial profiles will be obtained from the sequencing data using the specialized tools DADA2 and Kraken.
The search of characteristic signature of ScS will be performed by comparing ScS patients and healthy controls using a discriminant linear analysis (LDA) using the specialized tool LEfSe Main objective is to identify, through longitudinal follow-up, significant differences in the composition of the intestinal microbiota of ScS patients and healthy control subjects (matched on age and sex) in order to define a microbial signature specific to the ScS.
Secondary objectives are to study the stability over time of the identified microbial signatures, and to determine a correlation between the composition of the microbiota obtained in the ScS patient and the severity of his symptoms (diffuse skin disease, pulmonary interstitial disease, digestive disease...)
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Eya TOUMI, PhD student
- Phone Number: 04 13 42 81 50
- Email: e.toumi@alphabio.fr
Study Locations
-
-
-
Marseille, France, 13003
- Recruiting
- Hôpital Européen Marseille
-
Contact:
- Chloé STAVRIS, MD
- Phone Number: 06 23 01 64 25
- Email: c.stavris@hopital-europeen.fr
-
Contact:
- Eya TOUMY, PhD student
- Phone Number: 04 13 42 81 50
- Email: e.toumi@alphabio.fr
-
Principal Investigator:
- Chloé STAVRIS, MD
-
Sub-Investigator:
- Laurent CHICHE, MD
-
Sub-Investigator:
- Philippe HALFON, MD
-
Sub-Investigator:
- Caroline CHARPIN, MD
-
Sub-Investigator:
- Frédérique RETORNAZ, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For ScS patients:
- Patients with ScS according to ACR criteria.
- Patients over 18 years old.
- Patients who have signed the consent to participate in this study.
For control subjects:
- Persons without diagnosis of ScS or any other chronic disease.
- Persons over 18 years old.
- Persons who have signed the consent to participate in this study
Exclusion Criteria:
1. Persons with severe anemia (Hb < 7 g/dL). 2. Persons who cannot read French. 3. For control subjects: Persons with a particular symptom (as an example of digestive disorders), or under long-term treatment related to another pathology.
4. Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.
5. Persons referred to the article L1121-5 to 1121-8 of the Public health code, namely :
- Pregnant, women in labour and breastfeeding mothers.
- Persons deprived of their liberty by a judicial or administrative decision.
- Persons undergoing psychiatric follow-up.
- Minors
- Persons of full-age who are subject to a legal protection measure or who are unable to express their consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ScS patients
Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
|
Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
|
Healthy subjects
Healthy subjects will provide one stool sample at inclusion.
|
Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences on gut microbiota composition (bacterial populations) of ScS overtime, at different taxonomic levels (from phyla to species if technique allows) versus healthy controls.
Time Frame: 7 months
|
The patient participation at the study will last 7 months, but healthy volunteers will provide stool sample only once at study entry and won't be followed after that.
|
7 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chloé STAVRIS, MD, Hôpital Européen Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-30 MEDIBIOTE 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
Mitsubishi Tanabe Pharma America Inc.CompletedDiffuse Cutaneous Systemic SclerosisSpain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Clinical Trials on stool sampling
-
Hôpital Européen MarseilleRecruiting
-
Lille Catholic UniversityHôpital CochinCompletedHelicobacter Pylori InfectionFrance
-
GlaxoSmithKlineCompletedRotaviral GastroenteritisUnited Arab Emirates
-
PiLeJeCompleted
-
Centre Hospitalier Universitaire de Saint EtienneWithdrawnAnorexia Nervosa | Eating DisorderFrance
-
Central Hospital, Nancy, FranceRecruitingInflammatory Bowel Diseases | Ulcerative ColitisFrance
-
Hôpital Européen MarseilleRecruiting
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisBrazil
-
Hôpital Européen MarseilleRecruiting
-
University Hospital, Strasbourg, FranceTerminated